KMTS Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
28.6M
+16.6%
24.6M
+8.8%
22.6M
+16.5%
19.4M
+12.4%
17.2M
Cost of Revenue
13.0M
+11.2%
11.6M
+4.5%
11.1M
+5.9%
10.5M
+9.6%
9.6M
Gross Profit
15.7M
+21.5%
12.9M
+13.0%
11.4M
+29.1%
8.9M
+16.0%
7.6M
Operating Expenses
55.0M
+15.4%
47.7M
+10.4%
43.2M
+14.4%
37.7M
-32.4%
55.8M
R&D
5.6M
+13.3%
5.0M
+1.9%
4.9M
+21.9%
4.0M
-25.7%
5.4M
SG&A
49.4M
+15.7%
42.7M
+11.5%
38.3M
+13.6%
33.7M
-33.2%
50.5M
Operating Income
-39344000
-13.2%
-34765000
-9.5%
-31755000
-10.0%
-28878000
+40.1%
-48212000
EBITDA
-37019000
-12.9%
-32782000
-11.6%
-29382000
-9.4%
-26850000
+42.1%
-46376000
Net Income
-38835000
-13.7%
-34166000
-4.2%
-32785000
-26.9%
-25826000
+49.5%
-51111000
EPS (Basic)
$-0.67
-9.8%
$-0.61
+4.7%
$-0.64
-28.0%
$-0.50
+65.0%
$-1.43
EPS (Diluted)
$-0.67
-9.8%
$-0.61
+4.7%
$-0.64
-28.0%
$-0.50
+65.0%
$-1.43
Shares (Diluted)
58.2M
+4.2%
55.8M
+8.7%
51.4M
+0.1%
51.3M
+32.6%
38.7M
Kestra Medical Technologies (KMTS) โ€” Financials